The US District Court for the Eastern District of Pennsylvania sends a second reverse-payment case to trial (Cephalon)

On January 28, 2015, Judge Mitchell Goldberg of the U.S. District Court for the Eastern District of Pennsylvania denied defendants’ summary judgment motions, sending the second reverse-payment-settlement case to trial. In King Drug Company of Florence v. Cephalon, 2015 WL 356913 (E.D. Pa. Jan. 18, 2015), Judge Goldberg found that plaintiffs “satisfied their burden of presenting evidence of anticompetitive effects” and that there existed a factual dispute on whether the settling parties’ justifications were “pretextual.” Id. at *1. Facts The case involves Cephalon’s Provigil, a wakefulness drug that treats sleep disorders. Id. at *2. Cephalon obtained a patent on certain formulations of the active ingredient in Provigil. Id. On December 24, 2002, four generic firms—Barr, Mylan, Ranbaxy, and

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Michael A. Carrier, The US District Court for the Eastern District of Pennsylvania sends a second reverse-payment case to trial (Cephalon), 28 janvier 2015, e-Competitions January 2015, Art. N° 71871

Visites 272

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues